Antifibrinolytic Agent [EPC]

6714 reported adverse events

Drugs of this class: TRANEXAMIC ACID AMINOCAPROIC ACID PRECIPITATED CALCIUM CARBONATE, DIBASIC CALCIUM PHOSPHATE, AMINOCAPROIC ACID, ALUMINIUM CHLOROHYDROXY ALLANTOINATE SILICON DIOXIDE, AMINOCAPROIC ACID SODIUM MONOFLUOROPHOSPHATE, PRECIPITATED CALCIUM CARBONATE, DIBASIC CALCIUM PHOSPHATE, AMINOCAPROIC ACID, ALUMINIUM CHLOROHYDROXY ALLANTOINATE CALCIUM CARBONATE, ALCLOXA, AMINOCAPROIC ACID, DIBASIC CALCIUM PHOSPHATE DIHYDRATE PRECIPITATED CALCIUM CARBONATE, ALUMINUM CHLOROHYDROXY ALLANTOINATE, AMINOCAPROIC ACID, DIBASIC CALCIUM PHOSPHATE HYDRATE PRECIPITATED CALCIUM CARBONATE, AMINOCAPROIC ACID, ALUMINIUM CHLOROHYDRIN ALLANTOINATE, DIBASIC CALCIUM PHOSPHATE HYDRATE PRECIPITATED CALCIUM CARBONATE, DIBASIC CALCIUM PHOSPHATE, ALUMINIUM CHLOROHYDROXY ALLANTOINATE, AMINOCAPROIC ACID SILICON DIOXIDE, AMINOCAPROIC ACID, ALUMINUM CHLOROHYDROXY ALLANTOINATE

These side effects are most commonly reported by patients taking drugs of the Antifibrinolytic Agent [EPC] class:

# Side effect Count
0 OFF LABEL USE 368
1 DRUG INEFFECTIVE 348
2 PAIN 294
3 PYREXIA 286
4 DEATH 256
5 ANXIETY 239
6 NAUSEA 232
7 VOMITING 232
8 RENAL FAILURE 231
9 PNEUMONIA 224
See all common reactions for Antifibrinolytic Agent [EPC]

Drugs of the Antifibrinolytic Agent [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 POST PROCEDURAL HYPOTENSION 10 0.2778
1 URETERIC PERFORATION 5 0.1316
2 RED BLOOD CELL TRANSFUSION 6 0.0909
3 MESENTERIC VASCULAR INSUFFICIENCY 8 0.0769
4 HER2 POSITIVE BREAST CANCER 6 0.0556
5 HAEMOPHILIC ARTHROPATHY 5 0.0485
6 TRI-IODOTHYRONINE FREE DECREASED 9 0.0459
7 THORACOTOMY 5 0.0417
8 BILIARY SEPSIS 14 0.0376
9 FACTOR VIII INHIBITION 33 0.0338
See all enriched reactions for Antifibrinolytic Agent [EPC]